Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics‐Informed Pharmacogenomics

Major depressive disorder (MDD) is a common psychiatric disease. Selective serotonin reuptake inhibitors (SSRIs) are an important class of drugs used in the treatment of MDD. However, many patients do not respond adequately to SSRI therapy. We used a pharmacometabolomics‐informed pharmacogenomic research strategy to identify citalopram/escitalopram treatment outcome biomarkers. Metabolomic assay of plasma samples from 20 escitalopram remitters and 20 nonremitters showed that glycine was negatively associated with treatment outcome (P = 0.0054). This observation was pursued by genotyping tag single‐nucleotide polymorphisms (SNPs) for genes encoding glycine synthesis and degradation enzymes, using 529 DNA samples from SSRI‐treated MDD patients. The rs10975641 SNP in the glycine dehydrogenase (GLDC) gene was associated with treatment outcome phenotypes. Genotyping for rs10975641 was carried out in 1,245 MDD patients in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, and its presence was significant (P = 0.02) in DNA taken from these patients. These results highlight a possible role for glycine in SSRI response and illustrate the use of pharmacometabolomics to “inform” pharmacogenomics.

[1]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[2]  T. Sellers,et al.  Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. , 2008, Cancer research.

[3]  A. Bognar,et al.  Cloning and molecular characterization of three genes, including two genes encoding serine hydroxymethyltransferases, whose inactivation is required to render yeast auxotrophic for glycine. , 1994, The Journal of biological chemistry.

[4]  Francis J McMahon,et al.  Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. , 2006, American journal of human genetics.

[5]  K. Krishnan,et al.  Metabolomic mapping of atypical antipsychotic effects in schizophrenia , 2007, Molecular Psychiatry.

[6]  G. Jenkins,et al.  Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample , 2007, Biological Psychiatry.

[7]  J. Feighner,et al.  Antidepressants: Past, Present and Future , 2004, Handbook of Experimental Pharmacology.

[8]  Rima Kaddurah-Daouk,et al.  Metabolomics tools for identifying biomarkers for neuropsychiatric diseases , 2009, Neurobiology of Disease.

[9]  Takeshi Yamada,et al.  Short communication Correlation between plasma levels of glutamate, alanine and serine with severity of depression , 2006 .

[10]  A. Serretti,et al.  The pharmacogenomics of selective serotonin reuptake inhibitors , 2004, The Pharmacogenomics Journal.

[11]  C. Schmidt.  Metabolomics takes its place as latest up-and-coming "omic" science. , 2004, Journal of the National Cancer Institute.

[12]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Serretti,et al.  Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder , 2010, Molecular Psychiatry.

[14]  S. Rozen,et al.  Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study , 2009, Psychopharmacology.

[15]  G. Jenkins,et al.  A Genomewide Association Study of Citalopram Response in Major Depressive Disorder , 2010, Biological Psychiatry.

[16]  Stephan Ripke,et al.  A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. , 2009, Archives of general psychiatry.

[17]  S. Mikawa,et al.  Glycine cleavage system in neurogenic regions , 2004, The European journal of neuroscience.

[18]  K. Hiraga,et al.  Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. , 2008, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[19]  R. Weinshilboum,et al.  Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.

[20]  S. Rozen,et al.  Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia , 2010, Molecular Psychiatry.

[21]  H. Meltzer,et al.  Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. , 2004, The international journal of neuropsychopharmacology.

[22]  P. Muglia,et al.  Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. , 2010, The American journal of psychiatry.

[23]  H. Meltzer,et al.  Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression , 1995, European Neuropsychopharmacology.

[24]  F. Bloom,et al.  Introduction to Neuropsychopharmacology , 2008 .

[25]  S. Rozen,et al.  Opioid use affects antioxidant activity and purine metabolism: preliminary results , 2009, Human psychopharmacology.

[26]  B. Lewis,et al.  Detection of mutations in the glycine decarboxylase gene in patients with nonketotic hyperglycinaemia. , 2005, Molecular genetics and metabolism.

[27]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[28]  R. Weinshilboum,et al.  Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.

[29]  Elaine Holmes,et al.  Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis , 2004, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[30]  Y. Matsubara,et al.  Genomic deletion within GLDC is a major cause of non-ketotic hyperglycinaemia , 2006, Journal of Medical Genetics.

[31]  D. Schaid,et al.  SLC6A4 variation and citalopram response , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[32]  J. Markowitz,et al.  The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression , 2003, Biological Psychiatry.

[33]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[34]  N. Richard,et al.  Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. , 2005, The Journal of clinical psychiatry.

[35]  S. Turner,et al.  Identification and localization of multiple forms of serine hydroxymethyltransferase in pea (Pisum sativum) and characterization of a cDNA encoding a mitochondrial isoform. , 1992, The Journal of biological chemistry.

[36]  Rima Kaddurah-Daouk,et al.  Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases , 2009, Neuropsychopharmacology.

[37]  Y. Ohya,et al.  Human glycine decarboxylase gene ( GLDC) and its highly conserved processed pseudogene ( ψ GLDC) : their structure and expression, and the identification of a large deletion in a family with nonketotic hyperglycinemia , 2000 .

[38]  Y. Ohya,et al.  Human glycine decarboxylase gene (GLDC) and its highly conserved processed pseudogene (ψGLDC): their structure and expression, and the identification of a large deletion in a family with nonketotic hyperglycinemia , 2000, Human Genetics.